HOME >> BIOLOGY >> NEWS
Can The Economic Promise Of Drug Discovery Continue To Preserve The Suriname Forest?

as antifungal agents. In another example, graduate student John Berger has been able to enhance the anticancer activity of a new compound by synthesizing analogs, reports Kingston. "Now we're looking for others with more activity from which we can make analogs."

Meanwhile, Bristol-Myers Squibb has put more than 3,000 extracts through 32 screens each in six different therapeutic areas, with the result that one promising compound is continuing to be tested.

While looking for potential pharmaceutical products, project scientists conduct ethnobotanical and random botanical collections. Conservation International (CI) researchers collect plants that the shamans use to treat disease and injury. Such ethnobotanical collection is time consuming. The scientists must gain the shamans' trust to be able to go with them to collect plants. Meanwhile, researchers from the Missouri Botanical Garden (MBG) collect plants of interest at random and end up collecting more plants.

"So which collection strategy is the most productive?" the group wondered. The best way to test plants' activity, says Kingston, is to test it against its intended application. "If you have a plant that the shamans say promotes wound healing, you test it for that benefit. But we have not done that because we don't have tests that mimic whole-body responses."

Pharmaceutical companies are interested in the fundamental biochemistry of disease and have highly specific biochemical assays that they believe provide targets for novel compounds.

"We said to ourselves, 'These plants have been picked out over centuries by the shamans, so one would expect them to be more active than plants collected at random.' So we decided to compare the activity of extracts from plants collected by CI and the Missouri Botanical Garden," Kingston says.

Using yeast-based assays, the Virginia Tech researchers found there was a slight benefit to the ethnobotanical app
'"/>

Contact: David G.I. Kingston
dkingston@vt.edu
(540) 231-6570
Virginia Tech
31-Mar-1998


Page: 1 2 3 4

Related biology news :

1. Economic costs of extreme weather, state by state
2. Economic realities depleting arsenal of antiparasitic drugs
3. Economic model to aid alligator farmers
4. Multi Drug Resistant-TB: Russian Economic Collapse Will Lead To Global Spread Of "Ebola With Wings"
5. Good Ergonomics Is Good Economics
6. Penn State Eries Sea Grant To Focus On Ecology, Economic Development
7. New Gene Holds Promise For Controlling Crohns And Other Inflammatory Diseases
8. Continuing Research On Knee Surgery For Horses At Colorado State University Holds Promise Of Helping Humans With Osteoarthritis
9. New Protein-Like Polymer Shows Promise For Blood Vessel Replacement
10. Multicomponent Malaria Vaccine Shows Promise in Laboratory Tests
11. UD Valentine Science: Cell "Dating" Habits May Promise Healthier Hearts

Post Your Comments:
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/27/2015)... May 27, 2015 RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... it has commenced a public offering of shares ... of its common stock and overallotment purchase rights ... shares of common stock, warrants and overallotment purchase ...
(Date:5/27/2015)... , May 26, 2015 Research and ... the "Global Breast Cancer Monoclonal Antibodies Market ... Globally, Roche seems to dominate the breast ... Its block buster molecule, Herceptin has been able ... was found that breast cancer cells become recalcitrant ...
(Date:5/27/2015)... 27, 2015 Expanding in a big ... Avalon Biomed Inc. recently inked a deal ... Dental Co. Ltd. , the largest endodontic distributor in ... international market for Avalon Biomed, which manufactures Grey MTA ... silicate-based dental cements that have won renown from dentists ...
(Date:5/27/2015)... , May 27, 2015  Tikcro Technologies Ltd. (OTCQB: ... March 31, 2015. Aviv Boim ... continued pre-clinical work to generate functional specific antibodies, targeting ... stage, we are encouraged by the development progress. We ... new antibodies which modulate immune checkpoints gain clinical acceptance ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3
Cached News: